EndoChoice (GI) Posts Q2 Loss of 99c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
EndoChoice Receives FDA Clearance for Lumos™ with Adaptive Matrix Imaging
August 3, 2016 4:12 PM EDTALPHARETTA, Ga., Aug. 3, 2016 /PRNewswire/ -- EndoChoice Holdings, Inc. (NYSE: GI) announced the recent FDA clearance and US launch of Lumos with Adaptive Matrix Imaging. This novel and proprietary imaging software system will now be part of the Company's Generation 3 Fuse® Full Spectrum Endoscopy® System. EndoChoice scientists and engineers worked together to develop Lumos based upon Adaptive Matrix Imaging which analyzes and selectively enhances the vascularity, surface texture, and color of abnormal tissue, providing detailed information for physicians to assist in their detection of abnormalities during GI... More
